Skip to main content

Table 2 The proportion of C. albicans to NAC species and the first 3 dominant Candida species isolated in the current study compared to earlier studies between and with countries

From: Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia

 Clinical sampleCountry Reference
No, isolatesC. albicans, n (%)NAC n (%)  Dominate species 
194*104(49.8%)90 (43.1%)VariousEthiopiaC. albicans, C. krusei, C. fabata*
177139(78.5)38(21.5)Oral (HIV patientsEthiopiaC. albicans, C. glabrata,C. tropicalisMulu et al, 2013 [16]
8151(58.6)30(41.4)Vaginal swabEthiopiaC. albicans, C. krusei,C. dubliniesisBitew and Abebaw, 2018 [17]
6338(60.3)25(39.7)Vaginal swabEgyptC. albicans, C. glabrata, C. kruseiElFeky et al, 2016 [18]
11144(39.6)67(60.4)VariousIndiaC. albicans, C. krusei, C tropicalisMohandas & Balla 2011 [19]
9033(36.7)57(63.3)VariousIndiaC. albicans, C. tropicalis,C. parapsilosisDas et al 2016 [20]
10237(36.3)65(63.7)VariousIndiaC. tropicalis, C. albicans.C. guilliermondiiSida et al, 2017 [21]
250154(61.6)96(38.4)Oral cavityThailandC. albicans, C. glabrata, C. tropicalisMuadcheingka&Tantivitayakul,2015 [22]
10861(56.5)47(43.5)BloodTaiwanC. albicans, C. glabrata, C. tropicalisChi et al,2011 [23]
9033(36.7)57(63.3)VariousIndiaC. tropicalis, C.albicans. C. glabrataKaur et al, 2016 [24]
10380(77.8)23(22.3)Oral (HIV patients)BrazilC.albicans, C. tropicalis, C. parapsilosisRibeiro, et al, 2015 [25]
1062573(54)489 (46)VariousGermany &AustriaC. albicans, C. glabrata, C. parapsilosisSchmalreck et al, 2012 [26]
580420(72.4)160(27.6)Vaginal swabAmericaC. albicans, C. glabrata, C. parapsilosisRichter et al, 2005 [27]
428273(63.8)155(36.2)VariousIranC. albicans. C. tropicalis, C. parapsilosisBadiee et al, 2011 [28]
10343(42)60(58)BloodLatin AmericaC. albicans. C. tropicalis, C. parapsilosisGodoy et al, 2003 [29]
  1. * = current study